C
Christina L. Roland
Researcher at University of Texas MD Anderson Cancer Center
Publications - 142
Citations - 3577
Christina L. Roland is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Sarcoma. The author has an hindex of 24, co-authored 86 publications receiving 2060 citations. Previous affiliations of Christina L. Roland include American College of Surgeons & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
B cells are associated with survival and immunotherapy response in sarcoma.
Florent Petitprez,Aurélien de Reyniès,Emily Z. Keung,Tom Wei-Wu Chen,Cheng-Ming Sun,Cheng-Ming Sun,Julien Calderaro,Yung-Ming Jeng,Li Ping Hsiao,Laetitia Lacroix,Laetitia Lacroix,Antoine Bougoüin,Antoine Bougoüin,Marco Moreira,Marco Moreira,Guillaume Lacroix,Guillaume Lacroix,Ivo Natario,Ivo Natario,Julien Adam,Carlo Lucchesi,Yec′han Laizet,Maud Toulmonde,Melissa Amber Burgess,Vanessa Bolejack,Denise K. Reinke,Khalid M. Wani,Wei Lien Wang,Alexander J. Lazar,Christina L. Roland,Jennifer A. Wargo,Antoine Italiano,Catherine Sautès-Fridman,Catherine Sautès-Fridman,Hussein Abdul-Hassan Tawbi,Wolf H. Fridman,Wolf H. Fridman +36 more
TL;DR: Immune profiling of the tumour microenvironment of soft-tissue sarcoma identifies a group of patients with high levels of B-cell infiltration and tertiary lymphoid structures that have improved survival and a high response rate to immune checkpoint blockade therapy.
Journal ArticleDOI
A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice.
Bincy Philip,Christina L. Roland,Jaroslaw Daniluk,Yan Liu,Deyali Chatterjee,Sobeyda B. Gomez,Baoan Ji,Haojie Huang,Huamin Wang,Jason B. Fleming,Craig D. Logsdon,Zobeida Cruz-Monserrate +11 more
TL;DR: In mice, an HFD can activate oncogenic Kras via COX2, leading to pancreatic inflammation and fibrosis and development of PanINs and PDAC.
Journal ArticleDOI
Cell surface lactate receptor GPR81 is crucial for cancer cell survival
Christina L. Roland,Thiruvengadam Arumugam,Defeng Deng,Shi He Liu,Bincy Philip,Sobeyda B. Gomez,William R. Burns,Vijaya Ramachandran,Huamin Wang,Zobeida Cruz-Monserrate,Craig D. Logsdon +10 more
TL;DR: Examination of GPR81 expression and function in cancer cells found that it was present in colon, breast, lung, hepatocellular, salivary gland, cervical, and pancreatic carcinoma cell lines, and in vivo, G PR81 expression levels correlated with the rate of pancreatic cancer tumor growth and metastasis.
Journal ArticleDOI
Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts
Christina L. Roland,Sean P. Dineen,Kristi D. Lynn,Laura A. Sullivan,Michael T. Dellinger,Leila Sadegh,James P. Sullivan,David S. Shames,Rolf A. Brekken +8 more
TL;DR: Anti-VEGF therapy with bevacizumab, 2C3, or r84 inhibits the growth of established orthotopic MDA-MB-231 breast tumors in severe combined immunodeficiency mice, reduces tumor microvessel density, limits the infiltration of tumor-associated macrophages, but is associated with elevated numbers of tumors-associated neutrophils.
Journal ArticleDOI
Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab
Emily Z. Keung,Melissa Amber Burgess,Ruth Salazar,Edwin R. Parra,Jaime Rodrigues-Canales,Vanessa Bolejack,Brian A. Van Tine,Scott M. Schuetze,Steven Attia,Richard F. Riedel,James C. Hu,Scott H. Okuno,Dennis A. Priebat,Sujana Movva,Lara E. Davis,Damon R. Reed,Alexandre Reuben,Christina L. Roland,Denise K. Reinke,Alexander J. Lazar,Wei Lien Wang,Jennifer A. Wargo,Hussein Abdul-Hassan Tawbi +22 more
TL;DR: The findings support that multiple cell types present at the start of treatment may enhance tumor regression following anti–PD-1 therapy in specific advanced sarcomas and show that quantitative assessments of CD8+ CD3+ PD-1+ T cells, percentage of TAMs expressing PD-L1, and other T-cell densities correlate with sarcoma response to pembrolizumab and improved PFS.